trimethoprim--sulfamethoxazole-drug-combination and Hemorrhage

trimethoprim--sulfamethoxazole-drug-combination has been researched along with Hemorrhage* in 14 studies

Reviews

1 review(s) available for trimethoprim--sulfamethoxazole-drug-combination and Hemorrhage

ArticleYear
Pulmonary vasculitis.
    The American review of respiratory disease, 1986, Volume: 134, Issue:1

    The granulomatous vasculitides frequently involve the lung. These syndromes include Wegener's granulomatosis, allergic angiitis and granulomatosis, and the polyangiitis overlap syndrome. Although not a true systemic vasculitis, necrotizing sarcoid granulomatosis also represents a type of pulmonary vasculitis. It is clear that many infectious agents can cause a picture in the lung that can be confused with granulomatous vasculitis and that an infectious process must be ruled out before a diagnosis of pulmonary vasculitis can be established. Pulmonary vasculitis can be associated with the hypersensitivity vasculitides, and pulmonary hemorrhage can be secondary to pulmonary capillaritis. Therapy of the hypersensitivity vasculitides consists of removing the offending antigen and instituting a limited course of corticosteroids. If the vasculitis is secondary to an underlying disease, such as lymphoma, therapy should be directed at the primary disease. Combination therapy with cyclophosphamide and corticosteroids is effective in the systemic vasculitides and the 5-yr survival rate is approximately 90%.

    Topics: Adrenal Cortex Hormones; Azathioprine; Behcet Syndrome; Chlorambucil; Connective Tissue Diseases; Cyclophosphamide; Cyclosporins; Drug Combinations; Granuloma; Granulomatosis with Polyangiitis; Hemorrhage; Humans; Lung Diseases; Lymphomatoid Granulomatosis; Respiratory Tract Infections; Sulfamethoxazole; Syndrome; Takayasu Arteritis; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination; Vasculitis; Vasculitis, Leukocytoclastic, Cutaneous

1986

Trials

3 trial(s) available for trimethoprim--sulfamethoxazole-drug-combination and Hemorrhage

ArticleYear
Unintended effects of a computerized physician order entry nearly hard-stop alert to prevent a drug interaction: a randomized controlled trial.
    Archives of internal medicine, 2010, Sep-27, Volume: 170, Issue:17

    The effectiveness of computerized physician order entry (CPOE) systems has been modest, largely because clinicians frequently override electronic alerts.. To evaluate the effectiveness of a nearly "hard stop" CPOE prescribing alert intended to reduce concomitant orders for warfarin and trimethoprim-sulfamethoxazole, a randomized clinical trial was conducted at 2 academic medical centers in Philadelphia, Pennsylvania. A total of 1981 clinicians were assigned to either an intervention group receiving a nearly hard stop alert or a control group receiving the standard practice. The study duration was August 9, 2006, through February 13, 2007.. The proportion of desired responses (ie, not reordering the alert-triggering drug within 10 minutes of firing) was 57.2% (111 of 194 hard stop alerts) in the intervention group and 13.5% (20 of 148) in the control group (adjusted odds ratio, 0.12; 95% confidence interval, 0.045-0.33). However, the study was terminated early because of 4 unintended consequences identified among patients in the intervention group: a delay of treatment with trimethoprim-sulfamethoxazole in 2 patients and a delay of treatment with warfarin in another 2 patients.. An electronic hard stop alert as part of an inpatient CPOE system seemed to be extremely effective in changing prescribing. However, this intervention precipitated clinically important treatment delays in 4 patients who needed immediate drug therapy. These results illustrate the importance of formal evaluation and monitoring for unintended consequences of programmatic interventions intended to improve prescribing habits.. clinicaltrials.gov Identifier: NCT00870298.

    Topics: Anti-Infective Agents; Anticoagulants; Decision Making, Computer-Assisted; Decision Support Systems, Clinical; Drug Interactions; Drug Prescriptions; Drug Therapy, Computer-Assisted; Electronic Prescribing; Hemorrhage; Humans; Medical Order Entry Systems; Medication Errors; Medication Systems, Hospital; Odds Ratio; Philadelphia; Reminder Systems; Time Factors; Trimethoprim, Sulfamethoxazole Drug Combination; Warfarin

2010
Reduction in pneumonia mortality and total childhood mortality by means of community-based intervention trial in Gadchiroli, India.
    Lancet (London, England), 1990, Jul-28, Volume: 336, Issue:8709

    In a community-based intervention trial to reduce childhood mortality from pneumonia the intervention area included 58 villages (6176 children aged 0-4 years) and the control area 44 villages (3947 children) in Gadchiroli, India. The interventions included mass education about childhood pneumonia and case-management of pneumonia by paramedics, village health workers, and traditional birth attendants (TBAs) who were trained to recognise childhood pneumonia and treat it with co-trimoxazole. Parents sought treatment, and coverage was 76% without active case-detection efforts. The case-fatality rate among the 612 cases treated by health workers was 0.8%, compared with 13.5% in the control area. After a year of intervention pneumonia-specific childhood mortality was significantly lower in the intervention than in the control area (8.1 vs 17.5 deaths per 1000 children under 5 years); the difference between the areas was greatest in children under 1 year. The differences in infant mortality (89 vs 121 per 1000) and total under-5 mortality (28.5 vs 40.7 per 1000) were highly significant. Mortality from other causes remained similar in the two areas but neonatal mortality due to birth injury and prematurity was significantly lower in the intervention area, presumably owing to the combination of better maternal and neonatal care by the TBAs trained in the project and the availability of treatment for pneumonia. The cost of co-trimoxazole was US $0.025 per child per year ($2.64 per child saved).

    Topics: Administration, Oral; Age Factors; Birth Injuries; Cause of Death; Child, Preschool; Community Health Services; Community Health Workers; Drug Administration Schedule; Evaluation Studies as Topic; Female; Health Education; Hemorrhage; Humans; India; Infant; Infant, Newborn; Infant, Premature, Diseases; Male; Pilot Projects; Pneumonia; Rural Health; Sampling Studies; Trimethoprim, Sulfamethoxazole Drug Combination

1990
Antibiotic prophylaxis and secondary haemorrhage following transurethral resection of the prostate: a prospective trial.
    British journal of urology, 1986, Volume: 58, Issue:4

    One hundred and sixty-two patients were studied in a random double-blind controlled trial of co-trimoxazole to prevent secondary haemorrhage following transurethral resection of the prostate (TURP). There was a significant correlation between the incidence of post-operative urinary infection and secondary haemorrhage (P less than 0.05) but no difference between the incidence of bleeding in the treatment and placebo groups. Although infection may play a role in the development of secondary haemorrhage, co-trimoxazole for 10 days does not decrease the incidence of this complication.

    Topics: Aged; Anti-Bacterial Agents; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Hemorrhage; Humans; Male; Middle Aged; Prostatectomy; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination

1986

Other Studies

10 other study(ies) available for trimethoprim--sulfamethoxazole-drug-combination and Hemorrhage

ArticleYear
Clinical Characteristics of Rapidly Progressive Fatal Hemorrhagic Pneumonia Caused by Stenotrophomonas maltophilia.
    Internal medicine (Tokyo, Japan), 2020, Volume: 59, Issue:2

    Objective Hemorrhagic pneumonia due to Stenotrophomonas maltophilia (SM) in severely immunocompromised patients has a very poor prognosis. However, the risk factors for hemorrhagic pneumonia are not clear. Methods This study assessed the predictive factors of hemorrhagic pneumonia caused by SM. The medical records of patients admitted to Osaka City University Hospital with SM bacteremia between January 2008 and December 2017 were retrospectively reviewed. Patients All patients who had positive blood cultures for SM were included in this study. They were categorized into two groups: the SM bacteremia with hemorrhagic pneumonia group and the SM bacteremia without hemorrhagic pneumonia group. The clinical background characteristics and treatments were compared between these groups. Results The 35 patients with SM bacteremia included 4 with hemorrhagic pneumonia and 31 without hemorrhagic pneumonia. Hematologic malignancy (p=0.03) and thrombocytopenia (p=0.04) as well as the prior use of quinolone within 30 days (p=0.04) were more frequent in the SM bacteremia patients with hemorrhagic pneumonia than in those without hemorrhagic pneumonia. The mortality of the SM bacteremia patients with hemorrhagic pneumonia was higher than that of those without hemorrhagic pneumonia group (p=0.02). Conclusion Patients with SM bacteremia who have hematologic malignancy, thrombocytopenia, and a history of using quinolone within the past 30 days should be treated with deliberation.

    Topics: Adult; Female; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Hemoptysis; Hemorrhage; Humans; Immunocompromised Host; Male; Middle Aged; Pneumonia, Bacterial; Prognosis; Quinolones; Retrospective Studies; Risk Factors; Stenotrophomonas maltophilia; Thrombocytopenia; Trimethoprim, Sulfamethoxazole Drug Combination

2020
Successful treatment of pulmonary haemorrhage and acute respiratory distress syndrome caused by fulminant Stenotrophomonas maltophilia respiratory infection in a patient with acute lymphoblastic leukaemia - case report.
    BMC infectious diseases, 2020, Sep-10, Volume: 20, Issue:1

    Stenotrophomonas maltophilia-induced pulmonary haemorrhage is considered a fatal infection among haematological patients. The outcome can be explained by the patients' immunity status and late diagnosis and treatment.. We present the rare case of successful outcome in a 61-year-old female who developed alveolar haemorrhage and acute respiratory distress syndrome 8 days after a chemotherapy session for her acute lymphoblastic leukaemia, in the context of secondary bone marrow aplasia. Stenotrophomonas maltophilia was isolated in sputum culture. The patient benefitted from early empirical treatment with colistin followed by trimethoprim/sulfamethoxazole, according to the antibiogram. Despite a severe initial clinical presentation in need of mechanical ventilation, neuromuscular blocking agents infusion, and ventilation in prone position, the patient had a favourable outcome and was discharged from intensive care after 26 days.. Stenotrophomonas maltophilia severe pneumonia complicated with pulmonary haemorrhage is not always fatal in haematological patients. Empirical treatment of multidrug-resistant Stenotrophomonas maltophilia in an immunocompromised haematological patient presenting with hemoptysis should be taken into consideration.

    Topics: Anti-Bacterial Agents; Colistin; Drug-Related Side Effects and Adverse Reactions; Female; Gram-Negative Bacterial Infections; Hemorrhage; Humans; Immunocompromised Host; Middle Aged; Pneumonia, Bacterial; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pulmonary Alveoli; Respiratory Distress Syndrome; Sputum; Stenotrophomonas maltophilia; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination

2020
Granulomatosis with polyangiitis: potentially lethal gingival lesions presenting to the dentist.
    BMJ case reports, 2019, Apr-24, Volume: 12, Issue:4

    Gingival pathology is a daily presentation, however a small number of systemic conditions can manifest similar to a common gingival condition and have fatal results. Dentist referred 56-year-old woman to Oral and Maxillofacial Surgery department with a 2-week medical history of gingival bleeding not responding to local measures. Biopsy showed eosinophilic infiltrate and vasculitis, and blood tests showed positive markers including cytoplasmic antineutrophil cytoplasmatic antibodies. Granulomatosis with polyangiitis is a rare disease affecting the respiratory tract, blood vessels and kidneys. Oral lesions are rarely the primary presenting feature. When left untreated, most cases are fatal within a year of diagnosis. The diagnosis can only be made when certain criteria are found, including granular oral lesions exhibiting an eosinophilic inflammatory infiltrate on biopsy. With 5% of cases showing intraoral lesions as the primary feature, it is essential that dentists have the knowledge of this rare disease to refer and not to treat as a common gingival condition.

    Topics: Aftercare; Anti-Bacterial Agents; Antibodies, Antineutrophil Cytoplasmic; Biopsy; Dentists; Diagnosis, Differential; Eosinophils; Female; Giant Cells, Foreign-Body; Gingival Diseases; Glucocorticoids; Granulomatosis with Polyangiitis; Hemorrhage; Humans; Middle Aged; Oral Ulcer; Prednisolone; Rare Diseases; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination

2019
Preemptive warfarin dose reduction after initiation of sulfamethoxazole-trimethoprim or metronidazole.
    Journal of thrombosis and thrombolysis, 2017, Volume: 44, Issue:1

    To evaluate the utility of a preemptive warfarin dose reduction at the time of initiation of either sulfamethoxazole-trimethoprim or metronidazole, a retrospective chart review of patients who received an outpatient prescription for warfarin and either sulfamethoxazole-trimethoprim and/or metronidazole from July 1, 2011 to July 1, 2015 was conducted. Clinical outcomes compared Veterans who had a warfarin dose reduction and those who did not within 120 h (5 days) of antibiotic initiation. The primary outcome compared the pre-and post-antibiotic International Normalized Ratio (INR) of patients in the intervention group (warfarin dose reduction) with those in the control group (no intervention). Secondary outcomes assessed incidence of thromboembolic and major bleeding events within 30 days of antibiotic completion. Fifty patients were assessed. Forty-nine patients had at least one follow-up appointment; 126 follow-up visits were evaluated. There was a statistically significant difference for the change in therapeutic INR at the first follow-up appointment (p = 0.029) for those patients in the control group. On average, the patients in the intervention group required fewer follow-up visits (p = 0.019). There were no statistically significant differences for the overall rate of therapeutic INR values between groups, as well as no instances of a thromboembolic or major bleeding events during the follow-up period. Clinically significant differences were observed for patients who received a preemptive warfarin dose reduction upon initiation of sulfamethoxazole-trimethoprim or metronidazole. Patients in the intervention group required fewer follow-up appointments and were more likely maintain a therapeutic INR within the 30 days following the antibiotic course. Results of this study will be presented the at Pharmacy and Therapeutics committee in an effort to seek approval for policy development to initiate a local preemptive warfarin dose adjustment as a standard of practice.

    Topics: Adult; Aged; Aged, 80 and over; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Metronidazole; Middle Aged; Retrospective Studies; Thromboembolism; Trimethoprim, Sulfamethoxazole Drug Combination; Warfarin

2017
Risk of bleeding and antibiotic use in patients receiving continuous phenprocoumon therapy. A case-control study nested in a large insurance- and population-based German cohort.
    Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5

    There is major concern about coumarins interacting with various drug classes and increasing the risk of overanticoagulation. The aim of the study was to assess bleeding risk in patients with concurrent use of antibiotics and phenprocoumon, the most widely prescribed coumarin in many European countries. We conducted a nested-case-control study within a cohort of 513,338 incident and continuous phenprocoumon users ≥ 18 years of age using claims data of the statutory health insurance company AOK, covering 30% of the German population. Bleeding risk associated with current use of antibiotics for systemic use (antibacterials/antimycotics) was calculated using conditional logistic regression in 13,785 cases with a bleeding event and 55,140 risk-set sampling-matched controls. Bleeding risk associated with any antibacterial use in phenprocoumon users was significantly increased [odds ratio (OR) 2.37, 95% confidence interval (CI) 2.20-2.56]. The association was stronger for gastrointestinal than for cerebral bleeding (OR 2.09, 95% CI 1.84-2.38 and OR 1.34, 95% CI 1.03-1.74, respectively) and highest for other/unspecified bleeding (OR 2.92, 95% CI 2.62-3.26). Specific antibiotic classes were strongly associated with bleeding risk, e.g. cotrimoxazole (OR 3.86, 95% CI 3.08-4.84) and fluorquinolones (OR 3.13, 95% CI 2.74-3.59), among those highest for ofloxacin (OR 5.00, 95% CI 3.01-8.32). Combined use of phenprocoumon and antimycotics was not significantly associated with bleeding risk. Risk was not significantly modified by age (pint=0.25) or sex (pint=0.96). The association was stronger the closer the antibiotic exposure was to the bleeding event. Among continuous phenprocoumon users, antibiotics - particularly quinolones and cotrimoxazole - should be prescribed after careful consideration due to an increased bleeding risk. Close monitoring of international normalised ratio levels after prescription is recommended.

    Topics: Aged; Anti-Bacterial Agents; Anticoagulants; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Germany; Hemorrhage; Humans; Insurance, Health; Male; Middle Aged; Ofloxacin; Phenprocoumon; Population Groups; Risk; Trimethoprim, Sulfamethoxazole Drug Combination

2014
Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy.
    Transplant infectious disease : an official journal of the Transplantation Society, 2012, Volume: 14, Issue:4

    Pneumonia caused by Stenotrophomonas maltophilia is rare, but can be lethal in severely immunocompromised patients. However, its clinical course remains unclear.. Patients with pneumonia caused by S. maltophilia in Toranomon Hospital (890 beds, Tokyo, Japan) were reviewed retrospectively between April 2006 and March 2010.. During the study period, 10 cases of S. maltophilia pneumonia were identified. Seven patients had acute myeloid leukemia, 2 had myelodysplastic syndrome, and 1 had malignant lymphoma. All patients developed symptoms after allogeneic hematopoietic stem cell transplantation (HSCT). Five patients received first cord blood transplantation (CBT), 4 patients received second CBT, and 1 patient received first peripheral blood stem cell transplantation (PBSCT). The overall incidence of S. maltophilia pneumonia among 508 patients who received HSCT during the period was 2.0%. The incidence was 0% (0/95) in patients after bone marrow transplantation, 0.8% (1/133) after PBSCT, and 3.2% (9/279) after CBT. Pneumonia developed a median of 13.5 days (range, 6-40) after transplantation. At onset, the median white blood cell count was 10/μL (range, 10-1900), and the median neutrophil count was 0/μL (range, 0-1720). In all patients, S. maltophilia bacteremia developed with bloody sputum or hemoptysis. The 28-day mortality rate was 100%; the median survival after onset of pneumonia was 2 days (range, 1-10).. Hemorrhagic S. maltophilia pneumonia rapidly progresses and is fatal in patients with hematologic malignancy. Attention should be particularly paid to the neutropenic phase early after HSCT or prolonged neutropenia due to engraftment failure. A prompt trimethoprim-sulfamethoxazole-based multidrug combination regimen should be considered to rescue suspected cases of S. maltophilia pneumonia in these severely immunosuppressed patients.

    Topics: Adult; Anti-Bacterial Agents; Blood; Culture Media; Disease Progression; Female; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hemorrhage; Humans; Immunocompromised Host; Incidence; Japan; Male; Middle Aged; Pneumonia, Bacterial; Stenotrophomonas maltophilia; Time Factors; Trimethoprim, Sulfamethoxazole Drug Combination

2012
Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura.
    Internal medicine journal, 2012, Volume: 42, Issue:3

    We report the case of an 84-year-old man with refractory immune thrombocytopenia purpura (ITP) who was treated with rituximab and subsequently developed severe interstitial lung disease. There has been increasing use of rituximab in the treatment of ITP with success rates of up to 62% in adult patients with recurrent ITP. Interstitial lung disease is a rare but recognised complication of rituximab but has been rarely reported in the setting of ITP.

    Topics: Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Combined Modality Therapy; Disease Progression; Hemorrhage; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lung Diseases, Interstitial; Male; Pneumonia, Pneumocystis; Prednisone; Pulmonary Fibrosis; Purpura, Thrombocytopenic, Idiopathic; Rituximab; Tomography, X-Ray Computed; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine

2012
CPOE and clinical decision support in hospitals: getting the benefits: comment on "Unintended effects of a computerized physician order entry nearly hard-stop alert to prevent a drug interaction".
    Archives of internal medicine, 2010, Sep-27, Volume: 170, Issue:17

    Topics: Anti-Infective Agents; Anticoagulants; Decision Making, Computer-Assisted; Drug Interactions; Drug Prescriptions; Drug Therapy, Computer-Assisted; Electronic Prescribing; Hemorrhage; Humans; Medical Order Entry Systems; Medication Errors; Medication Systems, Hospital; Trimethoprim, Sulfamethoxazole Drug Combination; Warfarin

2010
Laparoscopic intra-abdominal ligation of the testicular artery following castration in a horse.
    Journal of the American Veterinary Medical Association, 2000, May-15, Volume: 216, Issue:10

    A 364-kg (800-lb) 1-year-old mixed-breed horse was admitted for treatment of uncontrolled bleeding after castration. Multiple attempts to ligate the testicular artery through the scrotal incisions prior to referral had been unsuccessful. Because of the owner's concerns about cost, an attempt was made to control the bleeding by applying pressure to the inguinal region and administering formalin IV. However, hemorrhage continued. A decision was made to use laparoscopy to ligate the testicular artery. The horse was anesthetized and positioned in dorsal recumbency, and a routine ventral laparoscopic approach was used. The horse recovered without further complications. Laparoscopy should be considered for ligation of the testicular artery in horses with uncontrolled bleeding after castration.

    Topics: Animals; Anti-Infective Agents, Urinary; Anti-Inflammatory Agents, Non-Steroidal; Arteries; Blood Transfusion; Clonixin; Gentamicins; Heart Rate; Hematocrit; Hemorrhage; Horse Diseases; Horses; Laparoscopy; Ligation; Male; Orchiectomy; Penicillin G; Phenylbutazone; Testis; Trimethoprim, Sulfamethoxazole Drug Combination

2000
Fulminant liver failure and pancreatitis associated with the use of sulfamethoxazole-trimethoprim.
    The American journal of gastroenterology, 1989, Volume: 84, Issue:12

    We report the case of a 26-yr-old patient with fulminant liver failure and acute hemorrhagic pancreatitis secondary to the use of trimethoprim-sulfamethoxazole (Bactrim DS). Our patient presented with skin rash and decreased C3 and C4 levels, which we believed was due to a hypersensitivity reaction secondary to the sulfonamide component (sulfamethoxazole). To our knowledge, this is the first case reported in which sulfamethoxazole-trimethoprim has been implicated as a cause of fulminant liver failure and acute hemorrhagic pancreatitis simultaneously, and emphasizes the need of discontinuing this medication as soon as there is evidence of liver and pancreatic dysfunction.

    Topics: Adult; Chemical and Drug Induced Liver Injury; Complement C3; Complement C4; Drug Hypersensitivity; Erythema; Hemorrhage; Humans; Male; Pancreatitis; Trimethoprim, Sulfamethoxazole Drug Combination

1989